Evolent Health (EVH) to Release Quarterly Earnings on Thursday

Evolent Health (NYSE:EVH) is scheduled to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of $0.21 per share for the quarter. Evolent Health has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, February 22nd. The technology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.13. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. The business had revenue of $556.06 million during the quarter, compared to analyst estimates of $541.87 million. On average, analysts expect Evolent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Evolent Health Trading Up 1.4 %

NYSE:EVH opened at $27.62 on Wednesday. Evolent Health has a 12-month low of $23.33 and a 12-month high of $35.83. The firm has a market capitalization of $3.19 billion, a P/E ratio of -21.75 and a beta of 1.57. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.01 and a quick ratio of 1.01. The business has a 50 day simple moving average of $31.15 and a 200 day simple moving average of $30.29.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on EVH. Citigroup assumed coverage on Evolent Health in a research report on Monday, April 22nd. They set a “buy” rating and a $40.00 price target for the company. Canaccord Genuity Group lowered their target price on Evolent Health from $45.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, March 28th. Oppenheimer began coverage on Evolent Health in a research note on Friday, March 1st. They set an “outperform” rating and a $45.00 price target for the company. JMP Securities boosted their price objective on Evolent Health from $37.00 to $38.00 and gave the stock a “market outperform” rating in a research report on Friday, February 23rd. Finally, William Blair reissued an “outperform” rating on shares of Evolent Health in a research report on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.70.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.